Increasing Societal Benefit From Cardiovascular Drugs.
Sign Up to like & getrecommendations! Published in 2022 at "Circulation"
DOI: 10.1161/circulationaha.122.059032
Abstract: During the past few years, several innovative treatments for noncommunicable chronic disease have become available, including SGLT2i (sodium-glucose cotransporter-2 inhibitors), GLP-1a (glucagon-like-peptide 1 agonists), ARNI (angiotensin receptor-neprilysin inhibitors), and finerenone, a selective nonsteroidal mineralocorticoid receptor… read more here.
Keywords: increasing societal; benefit cardiovascular; cardiovascular drugs; societal benefit ... See more keywords